139 related articles for article (PubMed ID: 1487409)
1. An extended phase II trial of ifosfamide plus mesna in malignant mesothelioma.
Falkson G; Hunt M; Borden EC; Hayes JA; Falkson CI; Smith TJ
Invest New Drugs; 1992 Nov; 10(4):337-43. PubMed ID: 1487409
[TBL] [Abstract][Full Text] [Related]
2. High-dose ifosfamide with mesna and granulocyte-colony-stimulating factor (recombinant human G-CSF) in patients with unresectable malignant mesothelioma.
Talbot SM; Rankin C; Taub RN; Balcerzak SP; Bhoopalam N; Chapman RA; Baker LH; Middleman EL; Antman KH
Cancer; 2003 Jul; 98(2):331-6. PubMed ID: 12872353
[TBL] [Abstract][Full Text] [Related]
3. Malignant pleural mesothelioma: phase II pilot study of ifosfamide and mesna.
Alberts AS; Falkson G; Van Zyl L
J Natl Cancer Inst; 1988 Jul; 80(9):698-700. PubMed ID: 3131539
[No Abstract] [Full Text] [Related]
4. A phase II trial of dose-escalated doxorubicin and ifosfamide/mesna in patients with malignant mesothelioma.
Dirix LY; van Meerbeeck J; Schrijvers D; Corthouts B; Prové A; van Marck E; Vermeire P; van Oosterom AT
Ann Oncol; 1994 Sep; 5(7):653-5. PubMed ID: 7993844
[TBL] [Abstract][Full Text] [Related]
5. A phase II evaluation of ifosfamide and mesna in unresectable diffuse malignant mesothelioma. A Southwest Oncology Group study.
Zidar BL; Metch B; Balcerzak SP; Pierce HI; Militello L; Keppen MD; Berenberg JL
Cancer; 1992 Nov; 70(10):2547-51. PubMed ID: 1423183
[TBL] [Abstract][Full Text] [Related]
6. Ifosfamide in malignant mesothelioma: a phase II study.
Andersen MK; Krarup-Hansen A; Mårtensson G; Winther-Nielsen H; Thylen A; Damgaard K; Olling S; Wallin J
Lung Cancer; 1999 Apr; 24(1):39-43. PubMed ID: 10403693
[TBL] [Abstract][Full Text] [Related]
7. Ambulatory 4-day continuous-infusion schedule of high-dose ifosfamide with mesna uroprotection and granulocyte colony-stimulating factor in advanced solid tumours: a phase I study.
Toma S; Palumbo R; Comandone A; Oliva C; Vincenti M; Bumma C; Rosso R
Ann Oncol; 1995 Feb; 6(2):193-6. PubMed ID: 7540421
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of ifosfamide plus mesna as first-line chemotherapy in women with metastatic breast cancer.
Ingle JN; Krook JE; Mailliard JA; Hartmann LC; Wieand HS
Am J Clin Oncol; 1995 Dec; 18(6):498-501. PubMed ID: 8526193
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of ifosfamide and mesna in refractory adenocarcinoma of the endometrium. A Gynecologic Oncology Group study.
Sutton GP; Blessing JA; Homesley HD; McGuire WP; Adcock L
Cancer; 1994 Mar; 73(5):1453-5. PubMed ID: 8111713
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of ifosfamide and mesna in nonsquamous carcinoma of the cervix: a Gynecologic Oncology Group study.
Sutton GP; Blessing JA; DiSaia PJ; McGuire WP
Gynecol Oncol; 1993 Apr; 49(1):48-50. PubMed ID: 8482560
[TBL] [Abstract][Full Text] [Related]
11. Continuous 5-day infusion of ifosfamide with mesna in inoperable pancreatic cancer patients: a phase II study.
Cerny T; Martinelli G; Goldhirsch A; Terrier F; Joss R; Fey MF; Brunner KW; Küpfer A
J Cancer Res Clin Oncol; 1991; 117 Suppl 4():S135-8. PubMed ID: 1795002
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: a Gynecologic Oncology Group Study.
Sutton GP; Blessing JA; Homesley HD; Berman ML; Malfetano J
J Clin Oncol; 1989 Nov; 7(11):1672-6. PubMed ID: 2509641
[TBL] [Abstract][Full Text] [Related]
13. A phase I study of prolonged ambulatory infusion of Ifosfamide with oral mesna.
Olver I; Keefe D; Myers M; Caruso D
Chemotherapy; 2005 May; 51(2-3):142-6. PubMed ID: 15886474
[TBL] [Abstract][Full Text] [Related]
14. Ifosfamide, mesna, and interferon-alpha2A combination chemoimmunotherapy in malignant mesothelioma: results of a single center in central anatolia.
Altinbas M; Er O; Ozkan M; Coskun HS; Gulmez I; Ekici E; Kaplan B; Eser B; Ozesmi M
Med Oncol; 2004; 21(4):359-66. PubMed ID: 15579920
[TBL] [Abstract][Full Text] [Related]
15. Ifosfamide and mesna: response and toxicity at standard- and high-dose schedules.
Antman KH; Elias A; Ryan L
Semin Oncol; 1990 Apr; 17(2 Suppl 4):68-73. PubMed ID: 2110386
[TBL] [Abstract][Full Text] [Related]
16. A randomized phase II study of ifosfamide/mesna/cisplatin plus G-CSF or etoposide/cisplatin plus G-CSF in advanced non-small cell lung cancer: a Cancer and Leukemia Group B study.
Graziano SL; Valone FH; Herndon JE; Crawford J; Richards F; Rege VB; Clamon G; Green MR
Lung Cancer; 1996 Jun; 14(2-3):315-29. PubMed ID: 8794413
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of ifosfamide and mesna in patients with advanced or recurrent squamous carcinoma of the cervix who had never received chemotherapy: a Gynecologic Oncology Group study.
Sutton GP; Blessing JA; McGuire WP; Patton T; Look KY
Am J Obstet Gynecol; 1993 Mar; 168(3 Pt 1):805-7. PubMed ID: 8456884
[TBL] [Abstract][Full Text] [Related]
18. A phase II study of ifosfamide in combination with etoposide and cisplatin in the treatment of extensive small cell lung cancer.
Evans WK; Stewart D; Logan D; Maroun J; Goss G; Shepherd FA; Latreille J; Warner E; Dahrouge S
Semin Oncol; 1992 Dec; 19(6 Suppl 12):51-6. PubMed ID: 1336622
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of ifosfamide in the treatment of metastatic hormone-refractory patients with prostatic cancer.
Mahjoubi M; Azab M; Ghosn M; Theodore C; Droz JP
Cancer Invest; 1990; 8(5):477-81. PubMed ID: 2124944
[TBL] [Abstract][Full Text] [Related]
20. A phase II Gynecologic Oncology Group trial of ifosfamide and mesna in advanced or recurrent adenocarcinoma of the endometrium.
Sutton GP; Blessing JA; DeMars LR; Moore D; Burke TW; Grendys EC
Gynecol Oncol; 1996 Oct; 63(1):25-7. PubMed ID: 8898163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]